<p>Precision BioSciences, Inc.（納斯達克代碼：DTIL - 獲取免費報告）董事 Geno Germano 於 12 月 16 日（星期二）購買了 3,000 股 Precision BioSciences 的股票。該股票的平均購買成本為每股 4.72 美元，總價值為 14,160.00 美元。購買後，該董事在公司持有 23,883 股，價值 112,727.76 美元。此次交易使其持股增加了 14.37%。該交易已在向美國證券交易委員會（SEC）的備案中披露，相關信息可通過 SEC 網站獲取。</p>
<p>獲取 <strong>Precision BioSciences</strong> 的提醒：</p>
<h2>Precision BioSciences 股票表現</h2>
<p>在週三的午盤交易中，DTIL 上漲 0.11 美元，達到 4.93 美元。該公司的股票交易量為 16,762 股，而其平均交易量為 270,651 股。該公司的流動比率為 3.45，速動比率為 3.45，債務與股本比率為 1.35。該股票的市值為 6537 萬美元，市盈率為-0.59，貝塔值為 1.11。該公司 50 日簡單移動平均線為 5.94 美元，200 日簡單移動平均線為 5.22 美元。Precision BioSciences, Inc.的 12 個月最低價為 3.61 美元，最高價為 8.82 美元。</p>
<p>Precision BioSciences（納斯達克代碼：DTIL - 獲取免費報告）最近於 11 月 3 日（星期一）公佈了季度財報。該公司報告本季度每股收益（EPS）為-1.84 美元，低於市場共識預期的-0.31 美元，差距為-1.53 美元。該公司在本季度的收入為 0.01 百萬美元，而市場共識預期為 540 萬美元。Precision BioSciences 的淨利潤率為-11,977.36%，股本回報率為-233.77%。去年同期，該公司每股收益為-2.25 美元。研究分析師預計 Precision BioSciences, Inc.在當前年度的每股收益將為-1.23 美元。</p>
<h2>分析師評級上調與下調</h2>
<p>另外，Weiss Ratings 在週一的研究報告中重申了對 Precision BioSciences 股票的 “賣出（e+）” 評級。兩位研究分析師給予該股票買入評級，一位給予賣出評級。根據 MarketBeat 的數據，Precision BioSciences 的共識評級為 “持有”，共識目標價為 47.00 美元。</p>
<p><strong>查看我們最新的 Precision BioSciences 股票報告</strong></p>
<h2>Precision BioSciences 的機構交易</h2>
<p>對沖基金最近調整了對該股票的持有。Geode Capital Management LLC 在第二季度將其在 Precision BioSciences 的持倉增加了 5.5%。Geode Capital Management LLC 目前持有 77,712 股該公司股票，價值 326,000 美元，此前在上個季度購買了 4,025 股。Bridgeway Capital Management LLC 在第二季度獲得了 Precision BioSciences 的新股份，價值約 260,000 美元。Corient Private Wealth LLC 在第二季度購買了 Precision BioSciences 的新股份，價值約 425,000 美元。Vanguard Personalized Indexing Management LLC 在第三季度購買了 Precision BioSciences 的新股份，價值 72,000 美元。最後，Vanguard Group Inc.在第三季度將其在 Precision BioSciences 的持倉增加了 21.5%。Vanguard Group Inc.目前持有 492,596 股該公司股票，價值 2,719,000 美元，此前在上個季度購買了 87,242 股。機構投資者和對沖基金持有該公司 37.99% 的股票。</p>
<h2>Precision BioSciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Precision BioSciences, Inc.是一家先進的基因編輯公司，開發用於基因編輯的體內基因編輯療法，包括基因消除、插入和切除。該公司提供 ARCUS 基因組編輯平台，用於 DNA 基因的插入、刪除和修復。它還提供 PBGENE-HBV，用於治療慢性乙型肝炎病毒（HBV），以消除共價閉合環狀 DNA，並直接切割和編輯，以及使整合的 HBV DNA 失活，旨在長期減少乙型肝炎表面抗原；PBGENE-PMM 用於治療與 m.3243 相關的原發性線粒體肌病（PMM），預計將提交 IND 和/或 CTA。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Precision BioSciences</li>
<li>如何知道購買哪種加密貨幣：投資者指南</li>
<li>工業領域的大規模突破：現在必須關注的三隻股票</li>
<li>如何一步一步購買便宜股票</li>
<li>三隻科技股下跌超過 60%——哪一隻值得購買？</li>
<li>為什麼特別股息對收入投資者來説可能是一個令人愉快的驚喜</li>
<li>25 年後，思科終於從互聯網泡沫崩潰中恢復過來</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Precision BioSciences 嗎？</h2>
<p>在考慮 Precision BioSciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Precision BioSciences 並不在名單上。</p>
<p>雖然 Precision BioSciences 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

DTIL

<p>Precision BioSciences 的董事 Geno Germano 以每股 4.72 美元的價格購買了 3,000 股，總計 14,160 美元，增加了 14.37% 的持股比例。該交易已向美國證券交易委員會（SEC）披露。該公司的股票表現顯示最近的交易價格為 4.93 美元，市值為 6,537 萬美元。分析師對該股票的評級不一，普遍維持 “持有” 評級，目標價格為 47.00 美元。機構投資者持有該股票的 37.99%</p>

<p>Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Geno Germano acquired 3,000 shares of Precision BioSciences stock in a transaction that occurred on Tuesday, December 16th. The stock was acquired at an average cost of $4.72 per share, with a total value of $14,160.00. Following the purchase, the director owned 23,883 shares in the company, valued at $112,727.76. The trade was a 14.37% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>Precision BioSciences, Inc.（納斯達克代碼：DTIL - 獲取免費報告）董事 Geno Germano 於 12 月 16 日（星期二）購買了 3,000 股 Precision BioSciences 的股票。該股票的平均購買成本為每股 4.72 美元，總價值為 14,160.00 美元。購買後，該董事在公司持有 23,883 股，價值 112,727.76 美元。此次交易使其持股增加了 14.37%。該交易已在向美國證券交易委員會（SEC）的備案中披露，相關信息可通過 SEC 網站獲取。</p>
</div><p>Get <strong>Precision BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Precision BioSciences</strong> 的提醒：</p>
</div><h2>Precision BioSciences Stock Performance</h2>
<div class="lb-trans"><h2>Precision BioSciences 股票表現</h2>
</div><p>DTIL traded up $0.11 during midday trading on Wednesday, reaching $4.93. The company's stock had a trading volume of 16,762 shares, compared to its average volume of 270,651. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. The stock has a market cap of $65.37 million, a P/E ratio of -0.59 and a beta of 1.11. The company has a fifty day simple moving average of $5.94 and a 200 day simple moving average of $5.22. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $8.82.</p>
<div class="lb-trans"><p>在週三的午盤交易中，DTIL 上漲 0.11 美元，達到 4.93 美元。該公司的股票交易量為 16,762 股，而其平均交易量為 270,651 股。該公司的流動比率為 3.45，速動比率為 3.45，債務與股本比率為 1.35。該股票的市值為 6537 萬美元，市盈率為-0.59，貝塔值為 1.11。該公司 50 日簡單移動平均線為 5.94 美元，200 日簡單移動平均線為 5.22 美元。Precision BioSciences, Inc.的 12 個月最低價為 3.61 美元，最高價為 8.82 美元。</p>
</div><p>Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $5.40 million. Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. During the same period last year, the firm earned ($2.25) EPS. Research analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.</p>
<div class="lb-trans"><p>Precision BioSciences（納斯達克代碼：DTIL - 獲取免費報告）最近於 11 月 3 日（星期一）公佈了季度財報。該公司報告本季度每股收益（EPS）為-1.84 美元，低於市場共識預期的-0.31 美元，差距為-1.53 美元。該公司在本季度的收入為 0.01 百萬美元，而市場共識預期為 540 萬美元。Precision BioSciences 的淨利潤率為-11,977.36%，股本回報率為-233.77%。去年同期，該公司每股收益為-2.25 美元。研究分析師預計 Precision BioSciences, Inc.在當前年度的每股收益將為-1.23 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Precision BioSciences in a research note on Monday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Precision BioSciences has a consensus rating of &#34;Hold&#34; and a consensus price target of $47.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在週一的研究報告中重申了對 Precision BioSciences 股票的 “賣出（e+）” 評級。兩位研究分析師給予該股票買入評級，一位給予賣出評級。根據 MarketBeat 的數據，Precision BioSciences 的共識評級為 “持有”，共識目標價為 47.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Precision BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 Precision BioSciences 股票報告</strong></p>
</div><h2>Institutional Trading of Precision BioSciences</h2>
<div class="lb-trans"><h2>Precision BioSciences 的機構交易</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company's stock valued at $326,000 after purchasing an additional 4,025 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in Precision BioSciences during the second quarter worth approximately $260,000. Corient Private Wealth LLC bought a new position in shares of Precision BioSciences during the 2nd quarter worth approximately $425,000. Vanguard Personalized Indexing Management LLC bought a new position in Precision BioSciences during the third quarter worth $72,000. Finally, Vanguard Group Inc. increased its position in Precision BioSciences by 21.5% in the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company's stock valued at $2,719,000 after buying an additional 87,242 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近調整了對該股票的持有。Geode Capital Management LLC 在第二季度將其在 Precision BioSciences 的持倉增加了 5.5%。Geode Capital Management LLC 目前持有 77,712 股該公司股票，價值 326,000 美元，此前在上個季度購買了 4,025 股。Bridgeway Capital Management LLC 在第二季度獲得了 Precision BioSciences 的新股份，價值約 260,000 美元。Corient Private Wealth LLC 在第二季度購買了 Precision BioSciences 的新股份，價值約 425,000 美元。Vanguard Personalized Indexing Management LLC 在第三季度購買了 Precision BioSciences 的新股份，價值 72,000 美元。最後，Vanguard Group Inc.在第三季度將其在 Precision BioSciences 的持倉增加了 21.5%。Vanguard Group Inc.目前持有 492,596 股該公司股票，價值 2,719,000 美元，此前在上個季度購買了 87,242 股。機構投資者和對沖基金持有該公司 37.99% 的股票。</p>
</div><h2>Precision BioSciences Company Profile</h2>
<div class="lb-trans"><h2>Precision BioSciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.</p>
<div class="lb-trans"><p>Precision BioSciences, Inc.是一家先進的基因編輯公司，開發用於基因編輯的體內基因編輯療法，包括基因消除、插入和切除。該公司提供 ARCUS 基因組編輯平台，用於 DNA 基因的插入、刪除和修復。它還提供 PBGENE-HBV，用於治療慢性乙型肝炎病毒（HBV），以消除共價閉合環狀 DNA，並直接切割和編輯，以及使整合的 HBV DNA 失活，旨在長期減少乙型肝炎表面抗原；PBGENE-PMM 用於治療與 m.3243 相關的原發性線粒體肌病（PMM），預計將提交 IND 和/或 CTA。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Precision BioSciences</li>
<li>How to Know Which Cryptocurrency to Buy: A Guide for Investors</li>
<li>Massive Breakout in Industrials: 3 Must-Watch Stocks Now</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Precision BioSciences</li>
<li>如何知道購買哪種加密貨幣：投資者指南</li>
<li>工業領域的大規模突破：現在必須關注的三隻股票</li>
<li>如何一步一步購買便宜股票</li>
<li>三隻科技股下跌超過 60%——哪一隻值得購買？</li>
<li>為什麼特別股息對收入投資者來説可能是一個令人愉快的驚喜</li>
<li>25 年後，思科終於從互聯網泡沫崩潰中恢復過來</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=DTIL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Precision BioSciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Precision BioSciences 嗎？</h2>
</div><p>Before you consider Precision BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Precision BioSciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Precision BioSciences 並不在名單上。</p>
</div><p>While Precision BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Precision BioSciences 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Precision BioSciences（納斯達克代碼：DTIL）的董事 Geno Germano 購買了 3,000 股股票